Gionata Buggiani

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Forty-eight-week safety of bimekizumab in psoriasis: focus on infectious comorbidities.

Forty-eight-week safety of bimekizumab in psoriasis: focus on infectious comorbidities.

Journal: Italian journal of dermatology and venereology

Published: December 11, 2025

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Journal: Dermatology practical & conceptual

Published: August 31, 2025

Risankizumab in very elderly patients in real-world practice.

Risankizumab in very elderly patients in real-world practice.

Journal: Italian journal of dermatology and venereology

Published: November 07, 2024

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis).

Journal: The Journal of dermatological treatment

Published: August 20, 2024

Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas.

Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areas.

Journal: Archives of dermatological research

Published: April 21, 2024

Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.

Journal: Italian journal of dermatology and venereology

Published: July 05, 2022

Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study.

Efficacy and safety of dimethylfumarate in elderly psoriasis patients: a multicentric Italian study.

Journal: The Journal of dermatological treatment

Published: July 28, 2021

Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis.

Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis.

Journal: Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia

Published: March 13, 2020

Treatments of vitiligo: what's new at the horizon.

Treatments of vitiligo: what's new at the horizon.

Journal: Dermatologic therapy

Published: December 15, 2012

Fractional CO2 laser: a novel therapeutic device for refractory necrobiosis lipoidica.

Fractional CO2 laser: a novel therapeutic device for refractory necrobiosis lipoidica.

Journal: Dermatologic therapy

Published: December 06, 2012

Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients.

Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients.

Journal: Dermatologic therapy

Published: October 11, 2012

Cutaneous necrotizing vasculitis: a rational therapeutic approach.

Cutaneous necrotizing vasculitis: a rational therapeutic approach.

Journal: Dermatologic therapy

Published: September 07, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026